“…As a GPCR (G protein-coupled receptor) member, DR is classified into D1-like (including DRD1 and DRD5) and D2-like (including DRD2, DRD3 and DRD4) families according to their coupled G proteins, Gαs or Gαi [ 17 , 18 ]. Many neurogenic diseases such as Parkinson and Alzheimer’s disease were associated with DR dysfunction and relevant agonists or antagonists are used to target DR for therapy or modified to generate effective probes for live imaging [ 19 , 20 , 21 , 22 , 23 ]. Since Zhang et al reported that compounds with affinity for DRs could modulate autophagy in a screen [ 24 ], functions of different DRs agonists and antagonists in autophagy have been examined in cells and animals [ 25 , 26 , 27 , 28 , 29 , 30 , 31 ].…”